A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022
Observational Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 and HZ Efficacy, Immunogenicity and Safety of HZ/su by Frailty Status
Sponsor: GlaxoSmithKline
Listed as NCT03563183, this observational or N/A phase trial focuses on Herpes Zoster and remains completed. Sponsored by GlaxoSmithKline, it has been updated 14 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed
-
May 2020 — Jan 2021 [monthly]
Completed
-
Dec 2019 — May 2020 [monthly]
Completed
-
Jul 2019 — Dec 2019 [monthly]
Completed
Status: Recruiting → Completed
-
Nov 2018 — Jul 2019 [monthly]
Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .